Opportunities and Difficulties in the Repurposing of HDAC Inhibitors as Antiparasitic Agents
Ongoing therapy for human parasite infections has a few known drugs but with serious side effects and the problem of drug resistance, impelling us to discover novel drug candidates with newer mechanisms of action. Universally, this has boosted the research in the design and development of novel medi...
Saved in:
Main Authors: | Tapas Kumar Mohapatra (Author), Reena Rani Nayak (Author), Ankit Ganeshpurkar (Author), Prashant Tiwari (Author), Dileep Kumar (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19
by: Hoda Awad, et al.
Published: (2022) -
Exploration of anti-inflammatory and hepatoprotective effect of curcumin on co-administration with acetylsalicylic acid
by: Tapas Kumar Mohapatra, et al.
Published: (2019) -
Alkanediamide-Linked Bisbenzamidines Are Promising Antiparasitic Agents
by: Jean J. Vanden Eynde, et al.
Published: (2016) -
Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
by: Elizabeth A. Thomas
Published: (2014) -
Repurposing Phosphodiesterase-5 inhibitors as chemoadjuvants
by: Amit K. Tiwari, et al.
Published: (2013)